Drugs of Abuse Testing Market (Products - Analyzers (Immunoassays, Chromatographic Devices, and Breath Analyzers), Rapid Testing Devices (Urine Testing and Oral Fluid Testing), and Consumables (Fluid Collection Devices); Sample Type: Saliva, Breath, Urine, Blood, and Hair and Sweat; Testing Type - Pain Management Testing, Criminal Justice Testing, and Work Place Screening; End-user: Hospitals, Diagnostic laboratories, On-the-spot Testing, and Forensic Laboratories)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Drugs of Abuse Testing market size is expected to hit around USD 11.7 billion by 2030 from valued at USD 6.84 billion in 2021 and growing at a CAGR of 7.1% from 2022 to 2030.

Key Takeaways:

• By drug type, the cannabis/marijuana segment hit highest revenue share of over 27% in 2021.
• In 2021, North America region captured revenue share of over 39.6%.
• By product, analyzers segment is expected to grow at a 5.7% CAGR from 2022 to 2030.
• North America drug of abuse testing market is expected to reach at a CAGR of 5.5% iover the forecast period 2022 to 2030.

Report Scope of the Drugs of Abuse Testing Market

The imposition of stringent laws mandating alcohol and illicit substance abuse testing is anticipated to drive the market during the forecast period. However, the violation of privacy rights while drug testing is considered a challenge and impedes the adoption of such testing services.

Workplace substance abuse is on the rise despite random tests being conducted by organizations. Commonly abused illicit drugs on the job are cannabis and cocaine. In the workplace, substance abuse might lead to significant loss of productivity, physical injuries, and even fatalities. On the basis of various drug abuse surveys, around 22.5% of people do not admit using alcohol or any illicit drugs during working hours. Around 1 in 10 respondents say that they come prepared to avoid the risk of random tests at the workplace. Therefore, there is a growing need for rapid and frequent drug of abuse testing at the workplace in order to minimize loss of productivity, absenteeism, and healthcare costs. However, with the COVID-19 crisis and subsequent lockdown scenarios throughout the world, people are staying at and working from home, which is expected to reduce the number of substance abuse cases at the workplace.

The National Institute on Drug Abuse (NIDA) has been established as one of the major federal agencies focused on supporting scientific research on drug use disorders and their consequences, thus improving public health. In March 2020, the NIDA issued a Notice of Special Interest (NOSI) highlighting the urgent need for research and data collection and analysis on the risks of COVID-19 infection in people suffering from substance use disorders. This pandemic is a potential threat to individuals who smoke tobacco or marijuana or try vaping, as the infection affects the lungs. This initiative aims at the submission of applications for Competitive Revisions to active grants, targeting research about SARS-CoV-2 infection risks in individuals with substance use disorders, especially with marijuana, nicotine, methamphetamine, and opioids.

Rising Abuse of Prescription Drugs and Increase in Use of Drug Abuse Testing among Private Employers Fuel Market Growth

In recent years, several nations across the globe including the U.S. are experiencing increased cases and death rates due to abuse of prescription drugs or nonmedical utilization of prescription drugs.

The National Institute of Drug Abuse (NIDA) states that approximately 52 million people have utilized prescription drugs for nonmedical reasons for minimum one time in their lifetime. Besides, youth populace from across the globe is seen increasing the use of several pain relievers such as OxyContin and Vicodin, which are considered abused prescription drugs. Due to incorrect prescription and addiction to prescription drugs, there is notable increase in comorbid illnesses among older population. Hence, continuous increase in the abuse of prescription drugs is increasing the sales of drugs of abuse testing products.

People consuming illicit drugs tend to be less productive at work, change their jobs frequently, and they frequently absent at workplaces. These factors can result into increased risks of workplace accidents. As a result, many organizations across the globe are emphasizing on regularly performing drugs of abuse tests. Hence, the demand for drug abuse testing by public and private employers is estimated to increase in the years to come.

North America: Dominant Region for Drugs of Abuse Testing Industry

Europe, North America, Middle East and Africa, Asia Pacific, and Latin America are some of the key regions of the drugs of abuse testing market. Of them, North America is dominant region in the market.

The market is estimated to gain promising sales opportunities in North America in years to come owing to factors such as rise in consumption of illicit drugs and the increase in the availability of insurance plans intended for expensive diagnosis tests in the region.

The nature of the global drugs of abuse testing market is highly fragmented due to existence of several international level players. This scenario represents the highly intense level of competition in the market.

Companies in the drugs of abuse testing market are using different strategies such as acquisitions, collaborations, regulatory approvals, and new products launches. Moreover, several enterprises are increasing investments in R&D projects to develop advanced products. Such initiatives are projected to help in the expansion of the drugs of abuse testing market.

Some of the prominent players in the Drugs of Abuse Testing Market include:

• Danaher Corporation
• LabCorp
• Abbott Laboratories
• Quest Diagnostics, Inc.
• Cordant Health Solutions
• DrugScan
• Legacy Medical Services
• Mayo Clinic Laboratories
• LGC Group
• Precision Diagnostics

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Drugs of Abuse Testing market

By Drug Type

• Alcohol
• Cocaine
• Marijuana/Cannabis
• LSD
• Opioids
• Others

By Sample Type

• Urine
• Saliva
• Blood
• Hair
• Breath
• Others

By Product

• Equipment
• Immunoassay Analyzers
• Chromatography Instruments
• Breath Analyzers
• Consumables
• Rapid Test Kits
• Reagents
• Others

By Application

• Medical Screening
• Monitoring Pain Management
• Forensic & Legal Information
• Employment Drug Testing
• Sports & Athletics Testing

By End User

• Workplaces
• Criminal Justice Systems
• Hospitals
• Research Labs

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Drugs of Abuse Testing industry analysis from 2022 to 2030 to identify the prevailing Drugs of Abuse Testing industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Drugs of Abuse Testing industry segmentation assists to detemine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Drugs of Abuse Testing industry trends, key players, market segments, application areas, and market growth strategies.